Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.982 EUR 1.12% Market Closed
Market Cap: 182.7m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one IPH stock under the Base Case scenario is 4.6 EUR. Compared to the current market price of 1.982 EUR, Innate Pharma SA is Undervalued by 57%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IPH Relative Value
Base Case
4.6 EUR
Undervaluation 57%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.5
P/S
P/S
Price to Sales
14.5
vs History
11
vs Industry
56
Median 3Y
5.7
Median 5Y
6.3
Industry
6.9
Forward
2.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-5.5
Industry
22.9
Forward
22.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-7.5
Industry
19.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
23.5
More Details
20.7
P/B
P/B
Price to Book Value
20.7
vs History
1
vs Industry
18
Median 3Y
4.6
Median 5Y
3.5
Industry
2.5
More Details
13.7
EV/S
EV/S
Enterprise Value to Sales
13.7
vs History
11
vs Industry
49
Median 3Y
5.7
Median 5Y
5.3
Industry
7.4
Forward
2.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
51
Median 3Y
5.2
Median 5Y
5.2
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
12
Median 3Y
-5
Median 5Y
-4.8
Industry
3.8
Forward
17.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-5
Industry
3.8
Forward
-20.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-6.9
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-7.2
Industry
3.5
More Details
12.1
EV/IC
EV/IC
Enterprise Value to IC
12.1
vs History
1
vs Industry
35
Median 3Y
3.2
Median 5Y
2.7
Industry
4.6
More Details

Multiples Across Competitors

IPH Competitors Multiples
Innate Pharma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Innate Pharma SA
PAR:IPH
182.7m EUR 14.5 -3.7 -3.5 -3.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 869 319.3 -165 728.7 -201 247.5 -198 951
US
Abbvie Inc
NYSE:ABBV
327.9B USD 5.7 78.9 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
152.5B USD 4.5 25.7 13.9 23
US
Gilead Sciences Inc
NASDAQ:GILD
138.3B USD 4.8 23.2 10.1 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.9B USD 10.4 -116.2 24.7 25.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 020.4 -515.5 -561.4 -546.4
AU
CSL Ltd
ASX:CSL
121.2B AUD 5.1 28.4 17.5 21.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.5B USD 4.7 14.6 13.1 14.7
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38.2B USD 16.3 -141.5 -632.4 -316.9
P/S Multiple
Revenue Growth P/S to Growth
FR
Innate Pharma SA
PAR:IPH
Average P/S: 3 170 129.5
14.5
79%
0.2
FR
Pharnext SCA
OTC:PNEXF
34 869 319.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 020.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
5%
0.9
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
29%
0.6
P/E Multiple
Earnings Growth PEG
FR
Innate Pharma SA
PAR:IPH
Average P/E: 34.2
Negative Multiple: -3.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 728.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.2
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28.4
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
7%
2.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -141.5 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Innate Pharma SA
PAR:IPH
Average EV/EBITDA: 15.7
Negative Multiple: -3.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 247.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.9
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -632.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Innate Pharma SA
PAR:IPH
Average EV/EBIT: 20.3
Negative Multiple: -3.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 951 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -316.9 N/A N/A

See Also

Summary
IPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
IPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IPH stock valuation using valuation multiples.
Wall Street Estimates
IPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.